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by ddPCR in lung cancer
Sang Hoon Lee, Eun Young Kim, Taehee Kim and Yoon Soo Chang*
Abstract
Background: The rate of diagnosis of advanced lung adenocarcinoma must be improved. In this study, we
compared the detection rates of EGFR-tyrosine kinase inhibitor-sensitizing mutations (mEGFRs) in bronchial washing
fluid (BWF) and the plasma of patients with lung adenocarcinoma using the tissue genotype as the standard
reference.
Methods: Paired blood and BWF specimens were collected from 73 patients with lung cancer. The tumor EGFR
mutation status was determined by genotyping of the plasma and BWF samples using droplet digital PCR (ddPCR).
Results: The study cohort included 26, 10, 10, and 27 patients with stage I, II, III, and IV disease. Of the 73 cases, 35
had a wild-type EGFR, and 19 had the L858R substitution and exon 19 deletion mutations. The areas under the
receiver operator characteristic curves for sensitivity vs. specificity of ddPCR were 0.895 [95% confidence interval (CI):
0.822–0.969] for BWF and 0.686 (95% CI: 0.592–0.780) for plasma (p < 0.001). The fractional abundance was higher in
BWF of the mEGFR-positive cases than in the plasma (p = 0.004), facilitating easy threshold setting and
discrimination between mEGFR-positive and negative cases. When genotyping results obtained using plasma and
BWF were compared for early lung cancer (stages I–IIIA), the diagnostic yields were significantly higher for BWF
ddPCR, and the same tendency was observed for the advanced stages, suggesting that the BWF data may reflect
the genotype status in early-stage patients.
Conclusions: The mEGFR genotyping results obtained using BWF showed a higher diagnostic efficacy than did
those obtained using the plasma. Thus, BWF-based genotyping may be a useful substitute for that using plasma in
lung cancer.
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Background
In 2018, approximately two million people were newly diag-
nosed with lung cancer worldwide, and 1.76 million died of
this devastating disease, accounting for 18.4% of all cancer-
related deaths [1, 2]. Because the associated symptoms are
not initially detectable and are similar to those of other re-
spiratory diseases, lung cancer is typically diagnosed in ad-
vanced stages, when the disease cannot be cured by
surgical resection. Thus, lung cancer is mainly treated with
chemotherapy, targeted agents, and immune checkpoint in-
hibitors, based on biomarkers, along with radiotherapy.
Owing to recent advances in translational research, the
outcomes and quality of life of patients with lung cancer
have greatly improved through the use of targeted therapy,
including EGFR-, ALK-, and ROS1-targeting agents, com-
pared with those of patients on conventional treatments,
such as chemotherapy [3]. In a landmark placebo-
controlled study, Iressa Survival Evaluation in Lung Can-
cer (ISEL), of advanced non-small cell lung cancer
(NSCLC) refractory to previous chemotherapy, the EGFR-
tyrosine kinase inhibitor (TKI) showed an efficacy in a
subset of the study population, suggesting the need for
biomarkers to predict therapeutic responses [4]. The
ISEL-associated IPASS trial, which identified an EGFR-
activating mutation [5], showed that the EGFR-TKI was
more effective in patients with lung adenocarcinoma, who
had EGFR-TKI-sensitizing mutations (mEGFRs) [6]. Fur-
ther phase III trials, which compared the outcomes of
first- or second-line EGFR-TKI treatments with those of
platinum doublets, confirmed the beneficial effects of
mEGFRs on the progression-free survival and response
rates in patients with lung adenocarcinoma [7]. Therefore,
it is important to identify target genes and accurately
manage lung cancer, and mEGFRs are considered strong
biomarkers for predicting the response to an EGFR-TKI.
Tissue biopsy specimens are used as part of the standard-
ized protocol to detect EGFR target mutations. However,
tissue biopsy is an invasive procedure, or it is impossible to
obtain tissue biopsy samples, depending on the patient’s
condition, tumor location, and size. Based on the flexible
bronchoscopy biopsy results, the sensitivity of lung cancer
diagnosis was 34% for peripheral tumors with a diameter <
2 cm and 63% for peripheral lesions with a diameter > 2 cm
[8]; these suboptimal diagnostic yields make the identifica-
tion of molecular biomarkers difficult. By contrast, 82.9% of
specimens obtained by percutaneous core needle biopsies
are appropriate for molecular marker analysis, with only
15.3% of the subjects experiencing pneumothorax and 9.4%
showing complications after chest tube insertion [9].
Liquid biopsy using plasma is a simple, easy-to-repeat,
and less invasive method, which may overcome the disad-
vantages and limitations of tissue biopsy. However, this
method exhibits some disadvantages, as different assay
platforms show different sensitivities and specificities and
are based on different analytical approaches [10]. Further-
more, circulating tumor DNA (ctDNA) only constitutes
0.1–1.0% of cell-free DNA (cfDNA) in the plasma, and the
half-life of ctDNA is approximately 90min. Thus, the re-
sults obtained using the plasma are less accurate than
those obtained by conventional tissue biopsy. By-products
from the flexible bronchoscopy procedure, such as bron-
chial washing fluid (BWF) and/or bronchoalveolar lavage
fluid (BALF), may be a useful alternative to biopsy speci-
mens. Bronchoscopy is routinely performed in patients
with suspected lung cancer, and BALF is a specific mater-
ial that can reflect characteristics of the lung compartment
[11]. Carvalho et al. [12] performed mass spectrometry of
BALF from 90 patients with suspected lung cancer and
found significantly different biomarkers between the lung
cancer and non-lung cancer groups. These studies suggest
that the use of BALF may be more effective than that of
plasma for diagnosing lung cancer.
Droplet digital PCR (ddPCR) is an advanced technique,
which shows high sensitivity and specificity for the detec-
tion of genetic alterations in ctDNA. Using a microfluidic
chip system, ddPCR generates up to 20,000 droplets, which
can be used to separate particular DNA fragments [13, 14].
Herein, we compared the performance of the ddPCR
platform for the detection of mEGFRs in lung adenocar-
cinoma using plasma, which is a standard for liquid
biopsy, and BWF, obtained during routine bronchoscopy.
Methods
Patients and clinical specimens
Paired blood and BWF specimens were collected from
73 patients with NSCLC between June 2016 and May
2019. The inclusion criteria were as follows: (1) patho-
logically proven NSCLC; (2) the tumor EGFR mutation
(NM_005228.5) status determined by genotyping of
tumor tissue, which was obtained simultaneously with
blood and BWF samples; and (3) informed consent
signed for the collection and use of BWF and blood
samples. Patients with rare mEGFRs were excluded from
the study. This study was performed in accordance with
the amended Declaration of Helsinki and was approved
by the independent hospital institutional review board
(approval no. 3–2016-0225 and 3–2017-0321).
BWF and blood samples were obtained at the time of
the initial visit for pathologic examination of lung tumor,
and the interval for securing paired specimens was less
than 24 h. Bronchoscopy was performed through the
mouth after sedation of the patient with midazolam and
fentanyl, and bronchial washing was performed using ap-
proximately 20mL of sterile 0.9% saline by wedging the
bronchoscope at a lung cancer site. BWF was collected as
a residue after sending the tissue specimen for routine
cytologic examination and microbial study. If the obtained
BWF specimen was less than 5mL, an additional
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specimen was obtained by bronchial washing once or
twice and processed within 3 h of collection by centrifuga-
tion at 1800×g for 10min at 4 °C. The supernatant was
stored at − 80 °C until analysis. Seven milliliters of blood
were collected in a Streck tube (Streck, La Vista, NE,
USA); the sample was transferred to the laboratory within
8 h of collection and centrifuged at 1800×g for 10min at
4 °C to obtain plasma, and the plasma was stored at −
80 °C. DNA was extracted from the plasma using the
QIAamp circulating nucleic acid kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Droplet digital PCR
ddPCR was performed according to the manufacturer’s
instructions (Bio-Rad, Hercules, CA, USA). mEGFRs
were detected using probes (Bio-Rad) for the E19del
(c.2235del15; p.E746_A750del) and L858R mutation
(c.2573 T > G; p.Leu858Arg). A549 cells were used as a
negative control. As positive controls, SNU1330 cells,
harboring an EGFR E19del mutation (homozygote), and
H1975 cells, containing the L858R and T790M muta-
tions, were used in each experiment.
Droplets were generated using a QX100 droplet gener-
ator (Bio-Rad), and PCR amplification was performed using
a thermal cycler (Bio-Rad). After PCR, droplets were
streamed in a single file on a QX200 droplet reader (Bio-
Rad) to count fluorescence-positive and fluorescence-
negative droplets. Data were processed using the
QuantaSoft software (Bio-Rad). The thresholds for the
ddPCR results were determined using QuantaSoft and then
manually inspected for further validation. The ddPCR re-
sults were considered to pass quality control when the
number of droplets was more than 9000 and the wild-type
gene sequence was present at more than 100 copies/mL
[12]. Only data that passed initial quality control were fur-
ther analyzed. Positivity was defined as the fractional abun-
dance (Fa) of ≥0.044% (sensitivity, 42.1%; specificity, 91.4%)
for the plasma samples and ≥ 0.015% for the BWF samples.
Statistical analysis
Categorical and continuous parameters were evaluated using
a chi-squared test and an independent samples t-test, respect-
ively. Spearman’s correlation was used to evaluate the relation-
ships between two variables. Areas under the curves (AUCs)
for sensitivity vs. specificity of plasma and BWF ddPCR were
calculated and compared using the pROC and gmodels R
packages, respectively. A p-value of less than 0.05 was consid-
ered significant. Statistical analyses were performed using
SPSS version 25.0 (SPSS, Inc., Chicago, IL, USA) or the R stat-
istical package ver. 3.5.3 (Institute for Statistics and Mathemat-
ics, Vienna, Austria; www.R-project.org).
Results
Demographic characteristics of the study population
Table 1 presents the characteristics of the enrolled cases.
The mean age of the study population was 65.3 ± 9.8
Table 1 Baseline characteristics of the study population
Total (n = 73) Early stage of lung cancer (n = 38) Advanced stage of lung cancer (n = 35)
Age (year) 65.3 ± 9.8 65.0 ± 8.1 65.7 ± 11.5
Sex (F/M) 35/38 (47.9/52.1) 20/18 (52.6/47.4) 15/20 (42.9/57.1)
Smoking status
Never smoker 45 (61.6) 25 (65.8) 20 (57.1)
Former smoker 22 (30.1) 10 (26.3) 12 (34.3)
Current smoker 6 (8.2) 3 (7.9) 3 (8.6)
Smoking amount (pack-year) 12.6 ± 21.4 11.3 ± 20.0 14.1 ± 23.2
Tumor type
Adenocarcinoma 65 (89.0) 32 (84.2) 33 (94.3)
Squamous cell carcinoma 7 (9.6) 5 (13.2) 2 (5.7)
Sarcomatoid carcinoma 1 (1.4) 1 (2.6) –
Tumor size (cm) 3.5 ± 2.0 3.0 ± 2.0 3.9 ± 1.9
Lung cancer stage
I/II/III/IV 26/10/10/27 26/10/2/− −/−/8/27
EGFR genotyping
Wild type 35 (47.9) 18 (47.4) 17 (48.6)
E19del 19 (26.0) 12 (31.6) 7 (20.0)
L858R 19 (26.0) 8 (21.1) 11 (31.4)
Note: Early stage refers to stage I - IIIA, and advanced stage refers to stage IIIB - IV
Abbreviation: E19del, (c.2235del15; p.E746_A750del); L858R, (c.2573 T > G; p.Leu858Arg)
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years; 38 (52.1%) patients were males, and 35 (47.9%) pa-
tients were females. Twenty-eight (38.4%) patients had a
history of smoking, and the mean lifetime smoking level
was 12.6 ± 21.4 pack-year. Nearly all enrolled patients
(89.0%) had adenocarcinoma, and one (1.4%) had pul-
monary sarcomatoid carcinoma. The mean longest
diameter of tumor was 3.5 ± 2.0 cm. Twenty-six patients
had stage I cancer; 10 each had stage II and stage III
cancer; and 27 had stage IV cancer. Of the 73 patients,
35 (47.9%) were found to have a wild-type EGFR, and 38
patients showed mutations in the EGFR-tyrosine kinase
domain, of which 19 patients had the L858R substitution
and 19 had E19del. Except the stage, other baseline char-
acteristics did not significantly differ between patients
with early (stages I–IIIA) and advanced (stages IIIB–IV)
lung cancer.
Prediction of tissue EGFR mutations using plasma and
BWF ddPCR
First, we compared the diagnostic yields of plasma
and BWF ddPCR for all cases. The AUCs were 0.717
[95% confidence interval (CI): 0.592–0.842] for L858R
detection in the plasma samples and 0.961 (95% CI:
0.901–1.000) for that in the BWF samples (Table 2
and Fig. 1A). Thus, the testing of BWF more accur-
ately predicted the presence of L858R in tumor tissue
than did that of the plasma, and the difference be-
tween the AUCs was significant (p < 0.001), based on
DeLong’s test for two correlated receiver operator
characteristic (ROC) curves. Similar results were ob-
tained for predicting the presence of E19del in tumor
tissue, with the AUC being only 0.632 (95% CI:
0.519–0.745) for plasma ddPCR and 0.858 (95% CI:
0.746–0.969) for BWF ddPCR (Table 2 and Fig. 1B).
Thus, BWF was also more useful than the plasma for
predicting E19del, and the difference between the
AUCs was significant (p < 0.001), as determined by
DeLong’s test for two correlated ROC curves.
By combining the results of L858R and E19del detec-
tion, variables were simplified, and the usefulness of the
plasma and BWF was compared for predicting the tissue
EGFR mutation status by ddPCR. The AUC for detect-
ing tumor EGFR mutations using the plasma samples
was 0.686 (95% CI: 0.592–0.780), whereas that using the
BWF samples was 0.895 (95% CI: 0.822–0.969), showing
a significant difference between the types of specimens
(p < 0.0001; DeLong’s test for two correlated ROC
curves). Comparison of the Fa value obtained from BWF
with that obtained from the plasma for each patient
showed that the former was significantly higher than the
latter in mEGFR-positive cases (p = 0.004; Wilcoxon
signed-rank test), indicating that BWF is more suitable
than plasma to easily distinguish the positivity or nega-
tivity of ddPCR results (Fig. 2).
Sensitivity of ddPCR for prediction of the EGFR mutation
status
The cutoff Fa value based on the results obtained for the
plasma samples was 0.044%, and that for the BWF sam-
ples was 0.015%. When these cutoff values were applied,
the sensitivity for predicting tissue E19del mutations
using the plasma samples was 31.6%, whereas that using
BWF was 68.4% (Fig. 3), demonstrating that BWF was
superior (p = 0.005; McNemar’s chi-squared test). Similar
results were obtained when predicting tumor tissue
L858R substitution; the sensitivity using the plasma sam-
ples was 47.4%, while that using BWF was 89.5% (p =
0.005; McNemar’s chi-squared test). The same findings
were obtained when comparing the usefulness of the
plasma and BWF in predicting the tissue EGFR mutation
status by combining the L858R and E19del values in one
variable (p < 0.0001; McNemar’s chi-squared test). The
results obtained using both types of specimens showed a
high specificity, with no significant difference observed
(data not shown).
BWF ddPCR showed good diagnostic yields
The detection rate of mEGFRs using the plasma sam-
ples was dependent on the disease stage. To confirm
whether the same findings can be obtained using
BWF, we investigated the mEGFR detection yields in
each sample type by dividing lung cancer into early
and advanced stages and then compared the detection
rates for each type of samples in each group (Table 3
and Fig. 3). In the early-stage group (stages I–IIIA;
n = 38), the AUC value of the plasma samples for
Table 2 Sensitivity, specificity, and concordance rate of ddPCR according to EGFR mutation
L858R E19del










Sensitivity (%) 47.37 89.47 31.58 68.42
Specificity (%) 98.15 96.30 94.44 98.15
Concordance rate 82.2% (60/73) 94.5% (69/73) 76.7% (56/73) 84.9% (62/73)
Abbreviation: BWF, bronchial washing fluid; AUC, area under curve; E19del, (c.2235del15; p.E746_A750del); L858R, (c.2573 T>; p.Leu858Arg)
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predicting tissue mEGFRs was 0.504, whereas that of
BWF was 0.768, showing a significant difference be-
tween the sample types (p = 0.008). Although the spe-
cificity was high for both sample types, the sensitivity
was only 15.0% for plasma ddPCR, while that for
BWF ddPCR was 65.0%. In the advanced-stage group
(stages IIIB–IV; n = 35), the AUC value obtained
using BWF (1.000; 95% CI: 0.899–1.000) was higher
than that obtained using the plasma (0.879; 95% CI:
0.724–0.964). These findings showed that the results
obtained using BWF predicted the tumor tissue
mEGFR status more accurately than did those ob-
tained using plasma (p = 0.043; DeLong’s test for two
correlated ROC curves).
The plasma and BWF data were highly specific; how-
ever, the sensitivity of BWF ddPCR was significantly
higher than that of plasma ddPCR. The values obtained
using BWF also accurately reflected the mEGFR status
in early- and advanced-stage tumors.
Discussion
This study showed that BWF liquid biopsy samples
more reliably reflected the tumor mEGFR status than
did plasma samples when using ddPCR. Additionally,
BWF could be used to analyze both L858R and
E19del mutations and produced more sensitive re-
sults than did plasma at different stages of lung
cancer.
Although tissue biopsy is the gold standard for mo-
lecular genotyping in lung cancer, liquid biopsy may play
an important role as a complementary method for tar-
geted gene detection and the prediction of the clinical
course or outcome [15, 16], as well as for the detection
of lung cancer at an early stage [17]. Liquid biopsy is a
Fig. 1 Comparison of receiver operator characteristic curves according to the sample type (plasma or BWF) and EGFR mutation genotype. A
L858R; B E19del; and C both L858R and E19del. BWF, bronchial washing fluid. Abbreviation: E19del, (c.2235del15; p.E746_A750del); L858R,
(c.2573 T > G; p.Leu858Arg).
Fig. 2 Example of differences in ddPCR results according to samples. Bronchial washing fluid (BWF 2 and 3) specimens showed clearly
distinguishable mutational droplets from those in plasma (Plasma 2 and 3) specimens. SNU 1330 is the positive control. Blue bars indicate FAM-
positive droplets, and green bars indicate HEX-positive droplets. Dark green bars indicate total droplets
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relatively non-invasive, safe, and simple procedure.
Therefore, it can be performed in patients with poor
medical conditions or when the location or size of lung
cancer makes biopsy difficult.
Many studies have shown the feasibility of liquid
biopsy for lung cancer, but some limitations remain
[13, 18]. Blood samples are mainly used for liquid
biopsy, including determination of ctDNA, circulating
tumor cells, platelets, exosomes, and microRNAs,
which provide specific genetic information on the
tumor. Although the proportion of ctDNA can vary
depending on the tumor burden, stage,
vascularization, and biological features, the value is
generally only 0.1–1.0%. Furthermore, ctDNA has a
relatively short half-life, from approximately 16 to
150 min [19]. Thus, if sample processing is delayed,
Fig. 3 Comparison of sensitivity and specificity of ddPCR according to the EGFR mutation genotype and lung cancer stage. A Total patients; B
patients with early-stage (I–IIIA) lung cancer; and C patients with advanced-stage (IIIB–IV) lung cancer. BWF, bronchial washing fluid. Abbreviation:
E19del, (c.2235del15; p.E746_A750del); L858R, (c.2573 T > G; p.Leu858Arg).
Table 3 Sensitivity, specificity, and concordance rate of ddPCR according to lung cancer stage
Early stage of lung cancer (n = 38) Advanced stage of lung cancer (n = 35)










Sensitivity (%) 15.0 65.0 72.2 100.0
Specificity (%) 100.0 88.9 100.0 100.0
Note: Early stage refers to stage I - IIIA, and advanced stage refers to stage IIIB - IV
Abbreviation: BWF, bronchial washing fluid; AUC, area under curve
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the experimental results would not reflect the precise
ctDNA level. To overcome this limitation, we froze
BWF and plasma within 3 and 8 h of collecting sam-
ples, respectively, and used Streck tubes, which main-
tain the stability of cfDNA for up to 14 days and
CTC for up to 7 days. Recently, Krug el al [20]. dem-
onstrated that compared with that of ctDNA, com-
bined use of exosomal RNA (exoRNA) and cfDNA
allowed the detection of activating EGFR mutations
and T790M mutation with improved sensitivity (96
and 90%, respectively). In particular, this approach re-
sulted in the largest improvement in sensitivity (26 to
74%) in patients with intrathoracic metastatic diseases.
Therefore, measuring exoRNA and ctDNA in BWF
specimens may greatly improve the detection of EGFR
mutations, even at an early stage of lung cancer; how-
ever, further studies are needed to evaluate this
possibility.
BAL plays a supporting role in the diagnosis of lung
cancer [21]. Since the 1980s, various studies have shown
the usefulness of BAL in the diagnosis of lung malignan-
cies [22]. BAL showed a diagnostic yield of 33–90% in
diffuse malignant pulmonary infiltrates, although the
value differed depending on the cancer type. In particu-
lar, in NSCLC, such as squamous cell carcinoma and
adenocarcinoma, the diagnostic yield was 50 and 77%,
respectively [22]. Park et al. [23] suggested that BALF
might be effective for determining the EGFR mutation
status. Although their study involved a small number of
subjects (n = 20), a high concordance rate (91.7%) was
observed between BALF and tissue for detecting EGFR
mutations using PNA-mediated PCR clamping and
PANAMutyper with fluorescence melting curve analysis.
However, there were only three patients with early-stage
lung cancer, and they did not show any difference in the
detection rate between BALF and plasma. Our study in-
cluded 38 patients with an early-stage lung cancer, and
the sensitivity of mEGFR detection was 65% using BWF
and only 15.0% using plasma. The use of BWF showed
great improvements in the sensitivity and diagnostic
yield compared with that of the plasma in the case of pa-
tients with an early stage of lung cancer. Therefore, we
suggest that BWF rather than plasma be used to detect
mutational variations, regardless of the lung cancer
stage.
There are various methods of mEGFR detection in
lung cancer using liquid biopsy samples. ddPCR, which
is based on the generation of ~ 20,000 droplets, is one of
the powerful advanced techniques for detecting rare
gene mutations. Sacher el al [24]. reported a sensitivity
of 82 and 74% in the detection of E19del and L858R mu-
tations, respectively, via ddPCR using liquid biopsy sam-
ples from patients with advanced lung cancer, and
Thress el al [25]. reported a sensitivity of 90% and a
specificity 100% in the case of the L858R mutation. In
our study, ddPCR also showed high sensitivity and speci-
ficity using both plasma and BWF for the detection of
mEGFRs in advanced-stage cancer.
Our study showed that BWF could be substituted for
tissue biopsy samples to confirm EGFR mutations, and
the use of BWF may shorten the time from the diagnosis
to treatment by avoiding delays for biopsy and confirm-
ation of biopsy results. BWF specimen collection is eas-
ier and safer in comparison with lung biopsy because
only simple bronchoscopy needs to be performed in the
former, for which hospitalization is not required.
Additionally, we investigated the relationship between
tumor size and the mEGFR detection rate. Although a
significant agreement between liquid biopsy and tissue
biopsy samples was expected regarding the mEGFR sta-
tus for larger-sized tumors, no significant association
was noted between the tumor size and mEGFR detection
rate for liquid biopsy and tissue biopsy samples (data
not shown). These findings suggest that the diagnostic
yield of ddPCR using BWF liquid biopsy samples mainly
depends on the disease stage rather than on tumor size.
However, further studies with larger sample sizes are
needed.
Conclusions
Compared with liquid biopsy using plasma, that using
BWF resulted in a more effective detection of mEGFRs
by ddPCR. Thus, BWF may be useful for avoiding inva-
sive tissue biopsy and associated complications, such as
pneumothorax or bleeding.
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